Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term dalteparin for cancer-associated venous thromboembolism
NL-OMON33828Phase 4Active, not recruiting
- Sponsor
- Eisai Co., Ltd.
- Start
- Aug 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dalteparin in venous thromboembolism (VTE), deep vein thrombosis (DVT) and pulmonary embolism (PE), sponsored by Eisai Co., Ltd. Started Aug 2010; status: active, not recruiting.
02
Drugs
dalteparin
03
Conditions
venous thromboembolism (VTE)deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on NL-OMON33828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33828.